A randomized phase III trial of combined paclitaxel, carboplatin, and radiation therapy followed by weekly paclitaxel or observation for patients with locally advanced inoperable non-small-cell lung cancer

Clinical Lung Cancer

Volumn 13, Issue 3, 2012, Pages 205-213

  Carter, Dennis L ^a   Garfield, David ^a   Hathorn, James ^a   Mundis, Richard ^a   Boehm, Kristi A ^a   Ilegbodu, Des ^a   Asmar, Lina ^a   Reynolds, Craig ^a  

^a US Oncology Research   (United States)

Author keywords

Adult; Community based; Human; Induction; Maintenance; Multicenter

Indexed keywords

CARBOPLATIN; PACLITAXEL;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DEHYDRATION; DRUG RESPONSE; DYSPHAGIA; ESOPHAGITIS; FATIGUE; FEMALE; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUROPATHY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; THROMBOCYTOPENIA; TREATMENT OUTCOME; WEAKNESS;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUNG NEOPLASMS; MAINTENANCE CHEMOTHERAPY; MALE; MIDDLE AGED; NEOPLASM STAGING; PACLITAXEL; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84859848960     PISSN: 15257304     EISSN: 19380690     Source Type: Journal    
DOI: 10.1016/j.cllc.2011.10.005     Document Type: Article

References (26)

1. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomized clinical trials. Non-small Cell Lung Cancer Collaborative Group. BMJ 1995; 311:899-909.
2. Sause W, Kolesar P, Taylor S IV, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group. Chest 2000; 117:358-64. (Pubitemid 30111583)
3. Choy H, Akerley W, Safran H, et al. Multiinstitutional phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. J Clin Oncol 1998; 16:3316-22. (Pubitemid 28481627)
4. Nguyen NP, Leonardo JM, Karlsson U, et al. Efficacy of combined radiation, paclitaxel and carboplatin for locally advanced non-small cell lung carcinoma. Anticancer Res 2002; 22:3429-35. (Pubitemid 36132808)
5. Frasci G, Comella P, Scoppa G, et al. Weekly paclitaxel and cisplatin with concurrent radiotherapy in locally advanced non-small-cell lung cancer: a phase I study. J Clin Oncol 1997; 15:1409-17. (Pubitemid 27167373)
6. Rajeswaran A, Trojan A, Burnand B, et al. Efficacy and side effects of cisplatin- and carboplatin-based doublet chemotherapeutic regimens versus non-platinum-based doublet chemotherapeutic regimens as first line treatment of metastatic non-small cell lung carcinoma: a systematic review of randomized controlled trials. Lung Cancer 2008; 59:1-11.
7. Choy H, DeVore RF 3rd, Hande KR, et al. Preliminary analysis of a phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small cell lung cancer. Semin Oncol 1997; 24(4 suppl 12):S12-21- 26.
8. Choy H, Akerley W, Safran H, et al. Paclitaxel plus carboplatin and concurrent radiation therapy for patients with locally advanced non-small cell lung cancer. Semin Oncol 1996; 23(6 suppl 16):117-9. (Pubitemid 27069002)
9. Choy H, Devore RF 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable nonsmall- cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000; 47:931-7. (Pubitemid 30345590)
10. Belani CP, Choy H, Bonomi P, et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small-cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23:5883-91.
11. Belani CP, Perry MC, LaRocca RV, et al. Maintenance therapy (MT) with weekly paclitaxel improves outcome for advanced non-small cell lung cancer (NSCLC) patients. J Clin Oncol 2005; 23(suppl): abstract 7143. Available at: www.asco.org. Accessed: September 18, 2011.
12. National Cancer Institute. Common Toxicity Criteria version 2.0. (CTC). Available at: http://ctep.cancer.gov/forms/CTCv20-4-30-992.pdf. Accessed: June 21, 2004.
13. Fleming ID, Cooper JS, Hensen DE, et al. Liver. In: AJCC Cancer Staging Manual 5th ed. Philadelphia, PA: Lippincott-Raven, 1997.
14. World Health Organization: WHO handbook for reporting results of cancer treatment. Geneva, Switzerland; Offset Publication No. 48; 1979.
15. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53:457-81.
16. Ratanatharathorn V, Lorvidhaya V, Kraipiboon P, et al. Phase II study of concurrent chemoradiotherapy for inoperable (bulky) stage III (A/B) non-small cell lung cancer (NSCLC): a preliminary report. J Med Assoc Thai 2000; 83:85-92. (Pubitemid 30235761)
17. Ratanatharathorn V, Lorvidhaya V, Maoleekoonpairoj S, et al. Phase II trial of paclitaxel, carboplatin, and concurrent radiation therapy for locally advanced non-small-cell lung cancer. Lung Cancer 2001; 31:257-65. (Pubitemid 32107021)
18. Socinski MA, Blackstock AW, Bogart JA, et al. Randomized phase II trial of induction chemotherapy followed by concurrent chemotherapy and dose-escalated thoracic conformal radiotherapy (74 Gy) in stage III non-small-cell lung cancer: CALGB 30105. J Clin Oncol 2008; 26:2457-63.
19. Yamamoto N, Nakagawa K, Nishimura Y, et al. Phase III study comparing secondand third-generation regimens with concurrent thoracic radiotherapy in patients with unresectable stage III non-small-cell lung cancer: West Japan Thoracic Oncology Group WJTOG0105. J Clin Oncol 2010; 28:3739-45.
20. El-Sharouni SY, Kal HB, Battermann JJ, et al. Sequential versus concurrent chemoradiotherapy in inoperable stage III non-small cell lung cancer. Anticancer Res 2006; 26:495-505. (Pubitemid 43206007)
21. Fournel P, Robinet G, Thomas P, et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Français de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 2005; 23:5910-7.
22. Vokes EE, Choy H, Gandara D, et al. Adjuvant and neoadjuvant treatments for NSCLC. Lung Cancer 2002; 38(suppl 4):29-35.
23. Vokes EE, Herndon JE 2nd, Kelley MJ, et al. Induction chemotherapy followed by chemoradiotherapy compared with chemoradiotherapy alone for regionally advanced unresectable stage III non-small-cell lung cancer: Cancer and Leukemia Group B. J Clin Oncol 2007; 25:1698-704. (Pubitemid 46797950)
24. Hanna N, Neubauer M, Yiannoutsos C, et al. Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: the Hoosier Oncology Group and U.S. Oncology. J Clin Oncol 2007; 26:5755-60.
25. Kelly K, Chansky K, Gasper LE, et al. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 2008; 26:2450-6.
26. Sulman EP, Komaki R, Klopp AH, et al. Exclusion of elective nodal irradiation is associated with minimal elective nodal failure in non-small cell lung cancer. Radiation Oncology 2009; 4:5. Available at: http://www.ro-journal. com/content/4/1/5. Accessed: September 18, 2011.